医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces License of PeptiDream’s Peptide Discovery Platform System (PDPS) Technology to Novartis

2015年04月02日 AM08:00
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that Swiss-based Novartis has exercised its option under their 2012 Strategic Alliance Agreement to obtain a nonexclusive license to PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. Under the terms of the Technology License Agreement, PeptiDream will receive multi-stage upfront technology access payments, and will be eligible to receive development milestones and royalties on future sales of products that arise from use of the PDPS technology.

Comments from Kiichi Kubota, CEO of PeptiDream Inc.

We are delighted with Novartis’s decision to internalize the PDPS technology under our 2012 Strategic Alliance Agreement, and this exercise further validates our PDPS technology as one of the best hit-finding/discovery platforms. The license agreement will significantly contribute to PeptiDream’s revenue both in the short term and has the potential to generate significant revenues long into the future.

About PeptiDream Inc.

PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System(PDPS) , a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics.

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-5790-9991 (Tokyo)
p-reid@peptidream.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists